GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Climb Bio Inc (NAS:CLYM) » Definitions » Pretax Margin %

CLYM (Climb Bio) Pretax Margin % : % (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Climb Bio Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Climb Bio's Pre-Tax Income for the three months ended in Dec. 2024 was $-8.42 Mil. Climb Bio's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Climb Bio's pretax margin for the quarter that ended in Dec. 2024 was %.

The historical rank and industry rank for Climb Bio's Pretax Margin % or its related term are showing as below:


CLYM's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -127.47
* Ranked among companies with meaningful Pretax Margin % only.

Climb Bio Pretax Margin % Historical Data

The historical data trend for Climb Bio's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Climb Bio Pretax Margin % Chart

Climb Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pretax Margin %
Get a 7-Day Free Trial - - - - -

Climb Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Climb Bio's Pretax Margin %

For the Biotechnology subindustry, Climb Bio's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Climb Bio's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Climb Bio's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Climb Bio's Pretax Margin % falls into.


;
;

Climb Bio Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Climb Bio's Pretax Margin for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-73.897/0
= %

Climb Bio's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-8.416/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Climb Bio  (NAS:CLYM) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Climb Bio Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Climb Bio's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Climb Bio Business Description

Traded in Other Exchanges
N/A
Address
20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Executives
Emily Pimblett officer: Chief Accounting Officer C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Valerie Morisset officer: Chief Scientific Officer C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ai Eti Llc 10 percent owner C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Judith Dunn director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Andrew David Levin director C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Simon Tate director C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Adam Joseph Rosenberg director C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
James B Bucher officer: EVP and General Counsel 11804 NORTH CREEK PARKWAY S, BOTHELL WA 98011
Ra Capital Nexus Fund Ii, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Erin Lavelle officer: COO & CFO C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Len Blavatnik other: Affiliate of 10% Owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
Liam Ratcliffe director C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Robert Azelby director, officer: Chief Executive Officer 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109